Nautilus Biotechnology, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Nautilus Biotechnology, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($13.57M) | Oct 28, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($15.03M) | Jul 31, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($16.61M) | Apr 29, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($16.45M) | Oct 28, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($18.01M) | Jul 31, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($18.73M) | Apr 29, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($15.88M) | Oct 29, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($15.81M) | Jul 30, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($14.97M) | Apr 30, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($14.06M) | Oct 31, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($14.69M) | Aug 2, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($15.76M) | May 2, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($14.50M) | Nov 1, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($10.71M) | Aug 2, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($8.41M) | May 3, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($3.98M) | Nov 2, 2021 |
| Q3 | 2020 | Jun 30, 2020 | ($11.7K) | Nov 13, 2020 |
| Q2 | 2021 | Jun 30, 2020 | ($3.36M) | Aug 10, 2021 |
| Q3 | 2020 | Mar 31, 2020 | $0 | Nov 13, 2020 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q1 | 2021 | Mar 31, 2021 | ($1.78M) | May 13, 2021 |
| Q3 | 2020 | Sep 30, 2020 | ($174.7K) | Nov 13, 2020 |